Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 244 participants.

Also called NCT05184088

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 244 participants (enrolled count) (from the registry)
Sponsor
Lantheus Germany GmbH (from the registry)
Registry
  • NCT NCT05184088
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Germany, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05184088. Allocation not applicable; no masking; primary purpose diagnostic. Start 2023-01-13 (actual); primary completion 2026-04-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Acronym
CArdiag
Condition
Cardiac Amyloidosis
Condition
AL Amyloidosis
Condition
ATTR Amyloidosis
Intervention (Drug)
[18F]florbetaben
Lead sponsor
Lantheus Germany GmbH (class: industry)
Collaborator
pharmtrace klinische Entwicklung GmbH (class: not stated)

Record details

Record id
cardio:ct-nct05184088
Content hash
ee456643bc9517a64ee8d238fa988e1ebae93384b459fc09205f533372a0b456